Outlook Therapeutics (NASDAQ: OTLK – Get an Assessment) had its price target reduced by HC Wainwright research analysts from $6.00 to $5.00 in a report on Friday, Benzinga reports. The company currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 385.44% from the company’s current price.
OTLK has been the subject of a number of other research reports. BTIG Research launched coverage on Outlook Therapeutics in a Monday, October 31 report. They set a “buy” rating and a price target of $7.00 for the company. Brookline Capital Management reiterated a “buy” rating on Outlook Therapeutics shares in a Monday, Oct. 3 report. Finally, Chardan Capital kicked off Outlook Therapeutics coverage in a Tuesday, September 13 report. They set a “buy” rating for the company.
Outlook Therapeutics trades down 2.8%
NASDAQ OTLK opened at $1.03 on Friday. The stock has a 50-day moving average of $1.03 and a 200-day moving average of $1.12. Outlook Therapeutics has a 12-month low of $0.68 and a 12-month high of $2.12. The company has a market capitalization of $235.06 million, a PE ratio of -3.12 and a beta of 0.63.
Institutional investors weigh in on Outlook Therapeutics
A number of hedge funds and other institutional investors have recently changed their positions in the company. BlackRock Inc. raised its position in Outlook Therapeutics shares by 12.9% in the first quarter. BlackRock Inc. now owns 6,680,116 shares of the company valued at $11,891,000 after purchasing an additional 761,356 shares last quarter. State Street Corp increased its stake in Outlook Therapeutics by 3.2% in the third quarter. State Street Corp now owns 1,949,069 shares of the company valued at $2,378,000 after acquiring an additional 59,730 shares in the last quarter. Vista Finance LLC increased its stake in Outlook Therapeutics by 3.7% in the second quarter. Vista Finance LLC now owns 1,020,370 shares of the company valued at $1,041,000 after acquiring 36,725 additional shares in the last quarter. Northern Trust Corp increased its stake in Outlook Therapeutics by 20.1% in the first quarter. Northern Trust Corp now owns 981,485 shares of the company valued at $1,747,000 after acquiring an additional 163,940 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Outlook Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 357,907 shares of the company valued at $437,000 after acquiring 25,958 additional shares in the last quarter. 10.61% of the shares are currently held by institutional investors and hedge funds.
About Outlook Therapeutics
(Get a rating)
Perspectives Therapeutics, Inc., a late-stage clinical-stage biopharmaceutical company, is focused on the development and commercialization of monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of the product candidate bevacizumab that is in a Phase III clinical trial for the treatment of wet age-related macular degeneration and other retinal diseases.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Before you consider Outlook Therapeutics, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Outlook Therapeutics didn’t make the list.
Although Outlook Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here